Physician profile
Michael A Sassower
NPI 1710945159
$5,676.72
in general payments reported to CMS, 2019-2025
31 companies · $923 in 2025
The $923 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,350 · 2020: $212 · 2021: $420 · 2022: $566 · 2023: $476 · 2024: $730 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699 · Consulting Fee: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.52 |
| Consulting Fee | $430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,461.50 | 2019 | |
| Boston Scientific Corporation | $968.65 | 2019-2024 | Watchman Access System |
| Edwards Lifesciences Corporation | $837.15 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $604.56 | 2021-2024 | |
| Abiomed | $360.35 | 2020-2025 | |
| Pfizer INC. | $317.29 | 2019-2025 | |
| Abbott Laboratories | $231.38 | 2022-2025 | Mitraclip |
| Merck Sharp & Dohme LLC | $127.50 | 2021-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.73 | 2019-2023 | Lifevest |
| Cardiovascular Systems INC. | $82.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $80.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $62.19 | 2021-2023 | Brilinta |
| Amgen INC. | $51.58 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $40.97 | 2024 | Camzyos |
| Philips North America LLC | $38.49 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $31.11 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $30.04 | 2019 | |
| Bracco Diagnostics INC. | $26.55 | 2022 | |
| Esperion Therapeutics, INC. | $23.95 | 2022 | |
| Cardinal Health 200 LLC | $22.46 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.13 | 2023 | Uptravi |
| Sanofi-Aventis U.S. LLC | $21.42 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $20.41 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.06 | 2020 | |
| Covidien Lp | $16.81 | 2019 | |
| Daiichi Sankyo INC. | $16.00 | 2024 | Injectafer |
| Novo Nordisk INC | $14.87 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $14.82 | 2024 | Onpattro |
| Scpharmaceuticals INC. | $14.29 | 2025 | |
| Biosense Webster, INC. | $11.21 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $8.14 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sassower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.